Abstract
Cefepime/sulbactam is a combined antibiotic with a wide spectrum of antimicrobial activity, including cefepime, the fourth-generation cephalosporin, and sulbactam, the beta-lactamase inhibitor, in a 1:1 ratio. Cefepime/sulbactam has a bactericidal effect: it causes a disorder in cell wall synthesis due to blockade of transpeptidase and a disorder in the formation of cross-links in peptidoglycan [1]. Today, the problem of antibiotic resistance is growing rapidly. In the WHO list, a critically high level of priority for the development of new antibiotics is occupied by infections caused by ESBL-producing gram-negative bacteria that are resistant to cephalosporins, as well as carbapenem-resistant Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa [2]. Infections caused by multiresistant bacteria are characterized by a longer course, require prolonged hospitalization, are very difficult to treat with modern antibacterial drugs, and increase the risk of death [3]. In this regard, a deeper study of the action of individual antibacterial drugs and their combination with β-lactamase inhibitors in the treatment of diseases caused by multiresistant microorganisms is crucial.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
